Inhaled Nitric Oxide Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Inhaled Nitric Oxide Market Size Analysis and Top Companies

The global inhaled nitric oxide market size is projected to hit around USD 2.21 billion by 2033 form USD 1.03 billion in 2023 and with at a CAGR of 7.95%. The major players operating in the inhaled nitric oxide market are Vero Biotech LLC, International Biomedical, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, Praxair, Inc., SLE, Getinge AB, and Others.

Market Report Coverage

Inhaled Nitric Oxide Key Players

• Vero Biotech LLC
• International Biomedical
• Bellerophon Therapeutics
• Mallinckrodt Pharmaceuticals
• Praxair, Inc.
• SLE
• Getinge AB

Recent Developments

• In May 2023, Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology firm advancing new biotherapeutics throughout its proprietary Anticalin technology stage for a respiratory disorder, and cancer, declared the safety survey of 10 mg dry powder amount safety cohort from the latest multi-center placebo-organized phase 2a study.
• In February 2023, Vero Biotech declared that the FDA accepted Genosyl, second-generation, for rebreathing anesthesia in the functional room setting. Vero Biotech made Genosyl for the delivery of inhaled nitric oxide, which underlines the second-generation Genosyl. The third-generation device recently obtained FDA approval has yet to be verified with rebreathing anesthesia.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344